N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma

Oncogene

Volumn 27, Issue 28, 2008, Pages 3999-4007

  Kang, J ^a   Rychahou, P G ^a   Ishola, T A ^a   Mourot, J M ^a   Evers, B M ^a,b   Chung, D H ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Angiogenesis; MYCN; Neuroblastoma; PI3K Akt; VEGF

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA; SOMATOMEDIN C; TENSIN; VASCULOTROPIN; WORTMANNIN;

ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; MYCN GENE; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; ONCOGENE C MYB; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATOR GENE; REGULATORY MECHANISM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOVIRIDAE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICROFILAMENT PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ADENOVIRIDAE; MAMMALIA;

EID: 46249116654     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.15     Document Type: Article

References (40)

1. Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, White EL et al. (2002). c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 16: 2530-2543.
2. Beppu K, Nakamura K, Linehan WM, Rapisarda A, Thiele CJ. (2005). Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res 65: 4775-4781.
3. Brodeur GM. (1990). Neuroblastoma - clinical applications of molecular parameters. Brain Pathol 1: 47-54.
4. Brodeur GM. (2003). Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.
5. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. (1984). Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121-1124.
6. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A et al. (2006). Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res 66: 8139-8146.
7. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E et al. (2006). Augmentation of tumor angiogenesis by a Mycactivated microRNA cluster. Nat Genet 38: 1060-1065.
8. Fotsis T, Breit S, Lutz W, Rossler J, Hatzi E, Schwab M et al. (1999). Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells. Eur J Biochem 263: 757-764.
9. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. (2002). Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277: 38205-38211.
10. Fukuzawa M, Sugiura H, Koshinaga T, Ikeda T, Hagiwara N, Sawada T. (2002). Expression of vascular endothelial growth factor and its receptor Flk-1 in human neuroblastoma using in situ hybridization. J Pediatr Surg 37: 1747-1750.
11. Goodman LA, Liu BC, Thiele CJ, Schmidt ML, Cohn SL, Yamashiro JM et al. (1997). Modulation of N-myc expression alters the invasiveness of neuroblastoma. Clin Exp Metastasis 15: 130-139.
12. Hamada K, Sasaki T, Koni PA, Natsui M, Kishimoto H, Sasaki J et al. (2005). The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 19: 2054-2065.
13. Hatzi E, Breit S, Zoephel A, Ashman K, Tontsch U, Ahorn H et al. (2000). MYCN oncogene and angiogenesis: down-regulation of endothelial growth inhibitors in human neuroblastoma cells. Purification, structural, and functional characterization. Adv Exp Med Biol 476: 239-248.
14. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004.
15. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. (2001). Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12: 363-369.
16. Kang J, Ishola TA, Baregamian N, Mourot JM, Rychahou PG, Evers BM et al. (2007). Bombesin induces angiogenesis and neuroblastoma growth. Cancer Lett 253: 273-281.
17. Kang J, Kamal A, Burrows FJ, Evers BM, Chung DH. (2006a). Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors. Anticancer Res 26: 1903-1908.
18. Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM, Chung DH. (2006b). MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem Biophys Res Commun 351: 192-197.
19. Kenney AM, Widlund HR, Rowitch DH. (2004). Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Development 131: 217-228.
20. Kurmasheva RT, Harwood FC, Houghton PJ. (2007). Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol Cancer Ther 6: 1620-1628.
21. Langer I, Vertongen P, Perret J, Fontaine J, Atassi G, Robberecht P. (2000). Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas. Med Pediatr Oncol 34: 386-393.
22. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. (2001). HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004.
23. Marimpietri D, Nico B, Vacca A, Mangieri D, Catarsi P, Ponzoni M et al. (2005). Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. Oncogene 24: 6785-6795.
24. Maris JM, Matthay KK. (1999). Molecular biology of neuroblastoma. J Clin Oncol 17: 2264-2279.
25. Meitar D, Crawford SE, Rademaker AW, Cohn SL. (1996). Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 14: 405-414.
26. Misawa A, Hosoi H, Tsuchiya K, Sugimoto T. (2003). Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN. Int J Cancer 104: 233-237.
27. Nakamura K, Martin KC, Jackson JK, Beppu K, Woo C-W, Thiele CJ. (2006). Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1{alpha} in neuroblastoma cells. Cancer Res 66: 4249-4255.
28. Nara K, Kusafuka T, Yoneda A, Oue T, Sangkhathat S, Fukuzawa M. (2007). Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. Int J Oncol 30: 1189-1196.
29. Oikawa T, Shimamura M. (1996). Potent inhibition of angiogenesis by wortmannin, a fungal metabolite. Eur J Pharmacol 318: 93-96.
30. Opel D, Poremba C, Simon T, Debatin KM, Fulda S. (2007). Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 67: 735-745.
31. Pession A, Trere D, Perri P, Rondelli R, Montanaro L, Mantovani W et al. (1997). N-myc amplification and cell proliferation rate in human neuroblastoma. J Pathol 183: 339-344.
32. Pore N, Jiang Z, Shu HK, Bernhard E, Kao GD, Maity A. (2006). Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 4: 471-479.
33. Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abraham R, Ashendel C et al. (1994). Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res 54: 2419-2423.
34. Raschella G, Negroni A, Giubilei C, Romeo A, Ferrari S, Castello MA et al. (1991). Transcription of N-myc and proliferation-related genes is linked in human neuroblastoma. Cancer Lett 56: 45-51.
35. Ribatti D, Raffaghello L, Pastorino F, Nico B, Brignole C, Vacca A et al. (2002). In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression. Int J Cancer 102: 351-354.
36. Schwab M, Westermann F, Hero B, Berthold F. (2003). Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 4: 472-480.
37. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY et al. (1985). Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111-1116.
38. Tan C, Cruet-Hennequart S, Troussard A, Fazli L, Costello P, Sutton K et al. (2004). Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 5: 79-90.
39. von Rahden BH, Stein HJ, Puhringer-Oppermann F, Sarbia M. (2006). c-myc amplification is frequent in esophageal adenocarcinoma and correlated with the upregulation of VEGF-A expression. Neoplasia 8: 702-707.
40. Zaizen Y, Taniguchi S, Noguchi S, Suita S. (1993). The effect of N-myc amplification and expression on invasiveness of neuroblastoma cells. J Pediatr Surg 28: 766-769.